Pharmacovigilance is the monitoring of medicines and treatments after they go on market sale. In 2012, we helped shepherd EU pharmacovigilance legislation towards more fulsome and clearer information to patients and measures which enabled the proper reporting of adverse effects.

BEUC campaigned alongside the European Medicines Agency to improve the post-market surveillance of drugs. One clear outcome includes the development in September 2013 of an inverted black triangle on medicines indicating further monitoring is needed.